The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer
 
Osvaldo Arén Frontera
No Relationships to Disclose
 
Hans J. Hammers
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; exelixis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
David F. McDermott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Bristol-Myers Squibb; Prometheus (Inst)
 
Pamela Salman
Consulting or Advisory Role - Lilly; Merck Serono; Novartis; Roche/Genentech
Speakers' Bureau - Lilly; Novartis; Roche/Genentech
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Benoit Beuselinck
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Ipsen; Pfizer
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Asim Amin
Consulting or Advisory Role - Merck
Speakers' Bureau - Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; Merck
 
Camillo Porta
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Pfizer
 
Saby George
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Exelixis; Genentech/Roche; Janssen Oncology; Novartis; Pfizer; Sanofi
Research Funding - Acceleron Pharma (Inst); Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Sergio Bracarda
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Janssen Oncology; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Novartis; Roche
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst)
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Brian I. Rini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Merck; Pfizer
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
M. Brent McHenry
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sabeen Fatima Mekan
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)